TY - JOUR AU - Arber, D. A. AU - Orazi, A. AU - Hasserjian, R. AU - Thiele, J. AU - Borowitz, M. J. AU - Beau, M. M. PY - 2016 DA - 2016// TI - The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-03-643544 DO - 10.1182/blood-2016-03-643544 ID - Arber2016 ER - TY - JOUR AU - Mesa, R. AU - Miller, C. B. AU - Thyne, M. AU - Mangan, J. AU - Goldberger, S. AU - Fazal, S. PY - 2016 DA - 2016// TI - Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2208-2 DO - 10.1186/s12885-016-2208-2 ID - Mesa2016 ER - TY - JOUR AU - Pardanani, A. AU - Guglielmelli, P. AU - Lasho, T. L. AU - Pancrazzi, A. AU - Finke, C. M. AU - Vannucchi, A. M. PY - 2011 DA - 2011// TI - Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients JO - Leukemia VL - 25 UR - https://doi.org/10.1038/leu.2011.161 DO - 10.1038/leu.2011.161 ID - Pardanani2011 ER - TY - JOUR AU - Hultcrantz, M. AU - Kristinsson, S. Y. AU - Andersson, T. M. AU - Landgren, O. AU - Eloranta, S. AU - Derolf, A. R. PY - 2012 DA - 2012// TI - Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.42.1925 DO - 10.1200/JCO.2012.42.1925 ID - Hultcrantz2012 ER - TY - JOUR AU - Gupta, V. AU - Hari, P. AU - Hoffman, R. PY - 2012 DA - 2012// TI - Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-05-399048 DO - 10.1182/blood-2012-05-399048 ID - Gupta2012 ER - TY - JOUR AU - Tefferi, A. AU - Guglielmelli, P. AU - Larson, D. R. AU - Finke, C. AU - Wassie, E. A. AU - Pieri, L. PY - 2014 DA - 2014// TI - Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-579136 DO - 10.1182/blood-2014-05-579136 ID - Tefferi2014 ER - TY - JOUR AU - Klampfl, T. AU - Gisslinger, H. AU - Harutyunyan, A. S. AU - Nivarthi, H. AU - Rumi, E. AU - Milosevic, J. D. PY - 2013 DA - 2013// TI - Somatic mutations of calreticulin in myeloproliferative neoplasms JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1311347 DO - 10.1056/NEJMoa1311347 ID - Klampfl2013 ER - TY - JOUR AU - Guglielmelli, P. AU - Rotunno, G. AU - Fanelli, T. AU - Pacilli, A. AU - Brogi, G. AU - Calabresi, L. PY - 2015 DA - 2015// TI - Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis JO - Blood Cancer J VL - 5 UR - https://doi.org/10.1038/bcj.2015.90 DO - 10.1038/bcj.2015.90 ID - Guglielmelli2015 ER - TY - JOUR AU - Asp, J. AU - Andreasson, B. AU - Hansson, U. AU - Wasslavik, C. AU - Abelsson, J. AU - Johansson, P. PY - 2016 DA - 2016// TI - Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome JO - Haematologica VL - 101 UR - https://doi.org/10.3324/haematol.2015.138958 DO - 10.3324/haematol.2015.138958 ID - Asp2016 ER - TY - STD TI - JAKAFI® (ruxolitinib). Full Prescribing Information, Incyte Corporation. Wilmington, DE, 2016. Available at: https://www.jakafi.com/pdf/prescribing-information.pdf. Accessed 8 Aug 2016. UR - https://www.jakafi.com/pdf/prescribing-information.pdf ID - ref10 ER - TY - BOOK PY - 2015 DA - 2015// TI - EU Summary of Product Characteristics PB - Novartis Pharmaceuticals Corporation CY - Basel, Switzerland ID - ref11 ER - TY - JOUR AU - Verstovsek, S. AU - Mesa, R. A. AU - Gotlib, J. AU - Levy, R. S. AU - Gupta, V. AU - DiPersio, J. F. PY - 2012 DA - 2012// TI - A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1110557 DO - 10.1056/NEJMoa1110557 ID - Verstovsek2012 ER - TY - JOUR AU - Harrison, C. AU - Kiladjian, J. J. AU - Al-Ali, H. K. AU - Gisslinger, H. AU - Waltzman, R. AU - Stalbovskaya, V. PY - 2012 DA - 2012// TI - JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1110556 DO - 10.1056/NEJMoa1110556 ID - Harrison2012 ER - TY - JOUR AU - Verstovsek, S. AU - Mesa, R. A. AU - Gotlib, J. AU - Levy, R. S. AU - Gupta, V. AU - DiPersio, J. F. PY - 2013 DA - 2013// TI - The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis JO - Br J Haematol VL - 161 UR - https://doi.org/10.1111/bjh.12274 DO - 10.1111/bjh.12274 ID - Verstovsek2013 ER - TY - JOUR AU - Verstovsek, S. AU - Mesa, R. A. AU - Gotlib, J. AU - Levy, R. S. AU - Gupta, V. AU - DiPersio, J. F. PY - 2015 DA - 2015// TI - Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I JO - Haematologica VL - 100 UR - https://doi.org/10.3324/haematol.2014.115840 DO - 10.3324/haematol.2014.115840 ID - Verstovsek2015 ER - TY - JOUR AU - Cervantes, F. AU - Vannucchi, A. M. AU - Kiladjian, J. J. AU - Al-Ali, H. K. AU - Sirulnik, A. AU - Stalbovskaya, V. PY - 2013 DA - 2013// TI - Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-02-485888 DO - 10.1182/blood-2013-02-485888 ID - Cervantes2013 ER - TY - JOUR AU - Harrison, C. N. AU - Vannucchi, A. M. AU - Kiladjian, J. J. AU - Al-Ali, H. K. AU - Gisslinger, H. AU - Knoops, L. PY - 2016 DA - 2016// TI - Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2016.148 DO - 10.1038/leu.2016.148 ID - Harrison2016 ER - TY - STD TI - National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 18 Oct 2016. UR - http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf ID - ref18 ER - TY - JOUR AU - Cervantes, F. AU - Dupriez, B. AU - Pereira, A. AU - Passamonti, F. AU - Reilly, J. T. AU - Morra, E. PY - 2009 DA - 2009// TI - New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-07-170449 DO - 10.1182/blood-2008-07-170449 ID - Cervantes2009 ER - TY - JOUR AU - Mesa, R. A. AU - Verstovsek, S. AU - Gupta, V. AU - Mascarenhas, J. O. AU - Atallah, E. AU - Burn, T. PY - 2015 DA - 2015// TI - Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I JO - Clin Lymphoma Myeloma Leuk VL - 15 UR - https://doi.org/10.1016/j.clml.2014.12.008 DO - 10.1016/j.clml.2014.12.008 ID - Mesa2015 ER - TY - JOUR AU - Deininger, M. AU - Radich, J. AU - Burn, T. C. AU - Huber, R. AU - Paranagama, D. AU - Verstovsek, S. PY - 2015 DA - 2015// TI - The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis JO - Blood VL - 126 UR - https://doi.org/10.1182/blood-2015-03-635235 DO - 10.1182/blood-2015-03-635235 ID - Deininger2015 ER - TY - JOUR AU - Quintás-Cardama, A. AU - Vaddi, K. AU - Liu, P. AU - Manshouri, T. AU - Li, J. AU - Scherle, P. A. PY - 2010 DA - 2010// TI - Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-04-214957 DO - 10.1182/blood-2009-04-214957 ID - Quintás-Cardama2010 ER - TY - JOUR AU - Quintás-Cardama, A. AU - Kantarjian, H. AU - Cortes, J. AU - Verstovsek, S. PY - 2011 DA - 2011// TI - Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3264 DO - 10.1038/nrd3264 ID - Quintás-Cardama2011 ER - TY - JOUR AU - Mesa, R. A. AU - Cortes, J. PY - 2013 DA - 2013// TI - Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-79 DO - 10.1186/1756-8722-6-79 ID - Mesa2013 ER - TY - BOOK AU - Gupta, V. AU - Harrison, C. N. AU - Hexner, E. O. AU - Al-Ali, H. K. AU - Foltz, L. AU - Montgomery, M. PY - 2015 DA - 2015// TI - The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib: an exploratory analysis of the COMFORT studies ID - Gupta2015 ER - TY - JOUR AU - Gangat, N. AU - Caramazza, D. AU - Vaidya, R. AU - George, G. AU - Begna, K. AU - Schwager, S. PY - 2011 DA - 2011// TI - DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.32.2446 DO - 10.1200/JCO.2010.32.2446 ID - Gangat2011 ER - TY - JOUR AU - Quintas-Cardama, A. AU - Kantarjian, H. AU - Pierce, S. AU - Cortes, J. AU - Verstovsek, S. PY - 2013 DA - 2013// TI - Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia JO - Clin Lymphoma Myeloma Leuk VL - 13 UR - https://doi.org/10.1016/j.clml.2013.01.001 DO - 10.1016/j.clml.2013.01.001 ID - Quintas-Cardama2013 ER -